Dermatologists face difficult questions about the safety of topical and systemic medications during pregnancy and lactation. Safety data regarding these medications can be limited to case studies, animal models, or small cohort studies that lack statistical power. Given the ethical complexities of pregnancy, randomized clinical trials evaluating the use of potentially teratogenic medications are often unfeasible; thus, large cohort studies are typically needed to inform practice.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Abel MK, Murase JE. Oral and Topical Terbinafine for Fungal Infections in Pregnancy. JAMA Dermatol. 2020;156(4):371–372. doi:10.1001/jamadermatol.2019.5036
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: